Drugs
| 短名 | |
| Journal Impact | 12.87 |
| 国际分区 | TOXICOLOGY(Q1) |
| 期刊索引 | SCI Q1中科院 1 区 |
| ISSN | 0012-6667, 1179-1950 |
| h-index | 188 |
| 国内分区 | 医学(1区)医学药学(1区)医学毒理学(1区) |
| Top期刊 | 是 |
阅读世界上最受尊敬的权威药物信息来源，及时了解治疗学的最新发展。 40 多年来，DRUGS 一直是药物和治疗学的权威期刊，提供由领先的国际临床医生和研究人员撰写的独立且重要的信息。我们享有盛誉的真正国际名誉编辑委员会确保提供最高质量的内容以支持临床决策。通过严格而全面的同行评审评估计划，DRUGS 提供了详细而客观的分析，涵盖了所有疾病领域的所有新的和已建立的药物疗法。
期刊主页投稿网址| 涉及主题 | 医学内科学生物心理学精神科药理学化学遗传学生物化学病理护理部药物治疗内分泌学外科重症监护医学免疫学麻醉 |
| 出版信息 | 出版商: Adis，出版周期: Monthly，期刊类型: journal |
| 基本数据 | 创刊年份: 1971，原创研究文献占比: 52.80%，自引率:0.80%， Gold OA占比: 29.44% |
| 平均审稿周期 | 网友分享经验：一般,3-8周 |
| 平均录用比例 | 网友分享经验：较难 |
期刊引文格式
这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Using Four Pillars of Therapy: The Time to Act is Now
2024-9-11
Donanemab: First Approval
2024-9-6
Long-Term Safety and Efficacy Evaluation of Travoprost Intracameral Implant Based on Pooled Analyses from Two Phase III Trials
2024-9-6
Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape
2024-9-6
Correction: Elafibranor: First Approval
2024-9-6
Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis
2024-9-5
Cefepime–Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination
2024-8-30
Ensifentrine: First Approval
2024-8-28
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine
2024-8-21
Imetelstat: First Approval
2024-8-20
Correction: Tegileridine: First Approval
2024-8-12
Anticoagulation in Chronic Kidney Disease
2024-8-9
Elafibranor: First Approval
2024-8-7
Bone Fragility in Diabetes and its Management: A Narrative Review
2024-8-5
Drug-Induced Pigmentation: A Review
2024-8-1
Therapeutic Potential of FXI Inhibitors: Hype or Hope?
2024-7-29
Ivonescimab: First Approval
2024-7-29
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
2024-7-26
Tunlametinib: First Approval
2024-7-22
Tarlatamab: First Approval
2024-7-18
Mavorixafor: First Approval
2024-7-15
Targeting DNA Damage Response Deficiency in Thoracic Cancers
2024-7-13
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future
2024-7-13
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
2024-7-6
Zolbetuximab: First Approval
2024-7-5
Givinostat: First Approval
2024-7-5
Nogapendekin alfa Inbakicept: First Approval
2024-7-5
Tovorafenib: First Approval
2024-7-5
Prevention of Rheumatoid Arthritis in At-Risk Individuals: Current Status and Future Prospects
2024-7-2
New and Evolving Treatments for Neurologic Dysphagia
2024-7-2
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
2024-7-1
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses
2024-6-28
Zastaprazan: First Approval
2024-6-25
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough
2024-6-21
Sotatercept: First Approval
2024-6-21
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews
2024-6-20
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease
2024-6-20
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model
2024-6-20
Correction: Iptacopan: First Approval
2024-6-17
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians
2024-6-15
Aprocitentan: First Approval
2024-6-4
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
2024-6-1
Therapeutic Potential of Lipoprotein(a) Inhibitors
2024-6-1
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions
2024-5-30
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
2024-5-29
Understanding Differences in Sex-Based Outcomes with Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
2024-5-29
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
2024-5-29
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
2024-5-28
Ensitrelvir Fumaric Acid: First Approval
2024-5-25
Tegileridine: First Approval
2024-5-21
帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理
投稿经验分享
分享我的经验，帮你走得更远